Support for Start-ups in Space Tech and Big Data Technology Centre and the University of Edinburgh.


Science Minister Sam Gyimah said: “Scotland has an outstanding reputation for science and innovation and the Higgs Centre will harness this creativity, helping disruptive start-ups and entrepreneurs create the products of tomorrow.


“Big data and space technology have endless opportunities and through our modern Industrial Strategy we are supporting our world leading innovators to help to build a Britain fi t for the future.”


Higgs Centre (Credit:STFC)


A new centre in Edinburgh is offering start-up companies direct access to world leading scientists, engineers and big data experts, as part of UK Government efforts to help boost productivity and innovation. The Higgs Centre for Innovation offers specialist expertise and support in space-related technology and big-data analytics; up to 12 companies will be based in the Centre at any one time and will work next to researchers and engineers from both STFC’s UK Astronomy


The Higgs Centre for Innovation is funded through a £10.7 million investment from the UK Government through STFC and STFC is also investing £2 million over the next fi ve years to operate the Centre. The Centre incorporates laboratories and working spaces for researchers and facilities suitable for businesses and includes a Business Incubation Centre (BIC) based on the successful European Space Agency model already in operation in the UK.


Operated by STFC, who are part of UK Research and Innovation, in partnership with the University of Edinburgh, the Centre will also support new academic activities and enable the University’s astronomy and astrophysics PhD students to work directly with start-up companies to solve real-world problems.


The Centre is named in honour of Professor Peter Higgs of the


The launch of the Higgs Centre for Innovation, attended by Professor Peter Higgs and officially opened by Professor Mark Thomson. (Credit:STFC)


University of Edinburgh, who was awarded the Nobel Prize for Physics in 2013 for his theoretical prediction of the Higgs boson.


46408pr@reply-direct.com


Julabo Opens New UK Office


Julabo employees toured the company, followed by a meal in relaxed atmosphere.


Almost 20 years ago, the Julabo subsidiary in the UK was basically a chair and a desk. The subsidiary now features a modern company building for a team of 6 employees, which meets all current requirements on a Julabo sales and service subsidiary and offers growth potential for the future.


Latest technology creates optimum conditions: the offi ces are modern – there is a large training room for product and application presentations as well as a separate warehouse and a fully equipped, signifi cantly expanded service centre, which can cover the complete Julabo portfolio on site.


The inauguration of the Julabo UK branch in Stamford


Julabo celebrated the offi cial opening of the new modern company building in Stamford, Lincolnshire. General Manager Markus Juchheim welcomed representatives from trade, construction management and fi nances as well as the project team to the opening celebration. After a champagne reception, guests and


The new, greatly expanded customer service has proven itself immediately after the move. It allows us to respond faster and more fl exibly to customer demands on site.


The investment establishes Julabo’s basis for future expansion of its activities in this important market.


46180pr@reply-direct.com


Queen’s Award Recognition for Breast Cancer Removal Company


The system helps to maximise the amount of healthy tissue left behind and determine whether the cancer has spread. These techniques can greatly improve the experience for patients, save vital hospital resources and have been shown to match current gold standards for accuracy in numerous clinical trials, said the company.


Launched in Europe in 2013, Endomag’s device has been used in over 30,000 breast cancer procedures, at 300 hospitals in 30 countries. More recently the Company has launched the device in the US and Canada where it has already been used in thousands of procedures across North America and is currently being evaluated by over a hundred hospitals. Major cancer centres including University of California, San Francisco and University Hospitals Seidman Cancer Center, Cleveland have already adopted the system into routine use.


Eric Mayes CEO Endomag


Surgical guidance company Endomag has received the Queen’s Award for Enterprise in Innovation for 2018, for its efforts in developing novel surgical tools for more accurate removal of breast cancer.


The company has developed a minimally invasive surgical guidance system using magnetic sensing and nanotechnology, allowing surgeons to locate early-stage breast cancers with greater precision.


Eric Mayes, CEO at Endomag said: “We’re so pleased to receive Royal recognition for what our team has been able to achieve. We pride ourselves on the relationships we’ve developed with clinicians across the world and actively use their expertise to help shape the products we develop.


It’s a particularly proud moment for me to know that UK businesses, like Endomag, are developing products that have real impact on people’s lives. It’s vitally important that we can demonstrate that the UK is able to lead on innovation and develop products and services that improve lives in all corners of the world.”


46397pr@reply-direct.com


Proposed Fund to Democratise Biotech Investment Opportunities


The Government has been called on to introduce a new venture capital fund structure that will give the public the opportunity to be partners in the UK’s biotech revolution. The UK Bioindustry Association said that the fund should be based on the successful Enterprise Innovation Scheme (EIS) and include a new ‘Holding Relief’, which will reward individuals with further income tax relief if they stay invested in the long-term.


The BIA’s proposed fund structure would offer income and capital gains tax reliefs with a minimal-bureaucracy system for claiming and allow pooling of capital in a diversifi ed portfolio to spread risk. Individuals who stay invested for longer-periods – which is critical for knowledge-intensive companies conducting R&D – will be rewarded with further income tax relief, the trade association said. Proposals include extending the time fund managers have to identify and invest in suitable companies compared to existing funds and allowing the trading of shares in the fund, with purchasers also benefi ting from tax reliefs, to improve liquidity.


BIA CEO Steve Bates said: “The UK has world-leading bioscience companies that are delivering for patients and investors but too few people have the opportunity to share in their fi nancial success. The fund structure we’re proposing will democratise opportunities to share in the success of UK bioscience and provide much-needed long-term capital for the UK’s most innovative companies.


“We are working with the government and the investment community to address the scale-up challenge for UK companies. This will take innovative solutions and if we can combine the UK’s strengths in FinTech and Biotech, I’m confi dent we can deliver the fi nance required for our companies to meet their global ambitions.”


The proposals from BIA were made in response to an HM Treasury consultation for a new fund structure as part of the Patient Capital Review.


In a separate consultation response, the BIA has also called for changes to Entrepreneurs’ Relief, which currently unfairly penalises bioscience company founders. The BIA has suggested abolishing the 5% shareholding requirement for founders to benefi t from the reduced capital gains tax rate. The change would only apply to founders of knowledge-intensive companies, which typically raise money through a series of fundraising rounds that dilute the founders’ shareholdings below 5%, meaning they currently are excluded from Entrepreneurs’ Relief.


46403pr@reply-direct.com


Page 1  |  Page 2  |  Page 3  |  Page 4  |  Page 5  |  Page 6  |  Page 7  |  Page 8  |  Page 9  |  Page 10  |  Page 11  |  Page 12  |  Page 13  |  Page 14  |  Page 15  |  Page 16  |  Page 17  |  Page 18  |  Page 19  |  Page 20  |  Page 21  |  Page 22  |  Page 23  |  Page 24  |  Page 25  |  Page 26  |  Page 27  |  Page 28  |  Page 29  |  Page 30  |  Page 31  |  Page 32  |  Page 33  |  Page 34  |  Page 35  |  Page 36